Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration

Buprenorphine is an opioid drug used in the management of pain and the treatment opioid addiction. Like other opioids, it is believed that it achieves these effects by altering functional neurotransmitter pathways and the expression of important transcription factors; cyclic AMP response element-bin...

Full description

Bibliographic Details
Main Authors: Sanelisiwe P. Xhakaza, Leon J. Khoza, Advaitaa M. Haripershad, Terisha Ghazi, Shanel Dhani, Cosmas Mutsimhu, Molopa J. Molopa, Nithia P. Madurai, Lorna Madurai, Sanil D. Singh, Nirmala D. Gopal, Hendrik G. Kruger, Thavendran Govender, Anil Chuturgoon, Tricia Naicker, Sooraj Baijnath
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221003000
id doaj-b42c9fa8e37146f58edcab0afc27107f
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Sanelisiwe P. Xhakaza
Leon J. Khoza
Advaitaa M. Haripershad
Terisha Ghazi
Shanel Dhani
Cosmas Mutsimhu
Molopa J. Molopa
Nithia P. Madurai
Lorna Madurai
Sanil D. Singh
Nirmala D. Gopal
Hendrik G. Kruger
Thavendran Govender
Anil Chuturgoon
Tricia Naicker
Sooraj Baijnath
spellingShingle Sanelisiwe P. Xhakaza
Leon J. Khoza
Advaitaa M. Haripershad
Terisha Ghazi
Shanel Dhani
Cosmas Mutsimhu
Molopa J. Molopa
Nithia P. Madurai
Lorna Madurai
Sanil D. Singh
Nirmala D. Gopal
Hendrik G. Kruger
Thavendran Govender
Anil Chuturgoon
Tricia Naicker
Sooraj Baijnath
Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration
Biomedicine & Pharmacotherapy
Buprenorphine
Opioid addiction
Brain-derived neurotrophic factor (BDNF)
Cyclic AMP response element-binding protein (CREB)
Neurotransmitters
author_facet Sanelisiwe P. Xhakaza
Leon J. Khoza
Advaitaa M. Haripershad
Terisha Ghazi
Shanel Dhani
Cosmas Mutsimhu
Molopa J. Molopa
Nithia P. Madurai
Lorna Madurai
Sanil D. Singh
Nirmala D. Gopal
Hendrik G. Kruger
Thavendran Govender
Anil Chuturgoon
Tricia Naicker
Sooraj Baijnath
author_sort Sanelisiwe P. Xhakaza
title Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration
title_short Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration
title_full Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration
title_fullStr Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration
title_full_unstemmed Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration
title_sort alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration
publisher Elsevier
series Biomedicine & Pharmacotherapy
issn 0753-3322
publishDate 2021-06-01
description Buprenorphine is an opioid drug used in the management of pain and the treatment opioid addiction. Like other opioids, it is believed that it achieves these effects by altering functional neurotransmitter pathways and the expression of important transcription factors; cyclic AMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) in the brain. However, there is a lack of scientific evidence to support these theories. This study investigated the pharmacodynamic effects of BUP administration by assessing neurotransmitter and molecular changes in the healthy rodent brain. Sprague-Dawley rats (150–200 g) were intranasally administered buprenorphine (0.3 mg/mL) and sacrificed at different time points: 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h post drug administration. LC-MS was used to quantify BUP and neurotransmitters (GABA, GLUT, DA, NE and 5-HT) in the brain, while CREB and BDNF gene expression was determined using qPCR. Results showed that BUP reached a Cmax of 1.21 ± 0.0523 ng/mL after 2 h, with all neurotransmitters showing an increase in their concentration over time, with GABA, GLUT and NE reaching their maximum concentration after 8 h. DA and 5-HT reached their maximum concentrations at 1 h and 24 h, respectively post drug administration. Treatment with BUP resulted in significant upregulation in BDNF expression throughout the treatment period while CREB showed patterns of significant upregulation at 2 and 8 h, and downregulation at 1 and 6 h. This study contributes to the understanding of the pharmacodynamic effects of BUP in opioid addiction by proving that the drug significantly influences NT pathways that are implicated in opioid addiction.
topic Buprenorphine
Opioid addiction
Brain-derived neurotrophic factor (BDNF)
Cyclic AMP response element-binding protein (CREB)
Neurotransmitters
url http://www.sciencedirect.com/science/article/pii/S0753332221003000
work_keys_str_mv AT sanelisiwepxhakaza alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT leonjkhoza alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT advaitaamharipershad alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT terishaghazi alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT shaneldhani alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT cosmasmutsimhu alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT molopajmolopa alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT nithiapmadurai alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT lornamadurai alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT sanildsingh alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT nirmaladgopal alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT hendrikgkruger alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT thavendrangovender alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT anilchuturgoon alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT tricianaicker alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
AT soorajbaijnath alterationsinneurotransmitterlevelsandtranscriptionfactorexpressionfollowingintranasalbuprenorphineadministration
_version_ 1721434694135840768
spelling doaj-b42c9fa8e37146f58edcab0afc27107f2021-05-20T07:45:17ZengElsevierBiomedicine & Pharmacotherapy0753-33222021-06-01138111515Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administrationSanelisiwe P. Xhakaza0Leon J. Khoza1Advaitaa M. Haripershad2Terisha Ghazi3Shanel Dhani4Cosmas Mutsimhu5Molopa J. Molopa6Nithia P. Madurai7Lorna Madurai8Sanil D. Singh9Nirmala D. Gopal10Hendrik G. Kruger11Thavendran Govender12Anil Chuturgoon13Tricia Naicker14Sooraj Baijnath15Catalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaDiscipline of Medical Biochemistry, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, 4001, South AfricaDiscipline of Medical Biochemistry, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, 4001, South AfricaViro Care (SA) Pty Ltd, 12 The Avenue East, Prospecton, Durban 4113, South AfricaViro Care (SA) Pty Ltd, 12 The Avenue East, Prospecton, Durban 4113, South AfricaViro Care (SA) Pty Ltd, 12 The Avenue East, Prospecton, Durban 4113, South AfricaViro Care (SA) Pty Ltd, 12 The Avenue East, Prospecton, Durban 4113, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaDepartment of Criminology, University of KwaZulu-Natal, Durban 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaDepartment of Chemistry, University of Zululand, Private Bag X1001, KwaDlangezwa 3886, South AfricaDiscipline of Medical Biochemistry, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South AfricaCatalysis and Peptide Research Unit, Department of Pharmaceutical Sciences, College of Health Science, University of KwaZulu-Natal, Durban, 4001, South Africa; Corresponding author.Buprenorphine is an opioid drug used in the management of pain and the treatment opioid addiction. Like other opioids, it is believed that it achieves these effects by altering functional neurotransmitter pathways and the expression of important transcription factors; cyclic AMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) in the brain. However, there is a lack of scientific evidence to support these theories. This study investigated the pharmacodynamic effects of BUP administration by assessing neurotransmitter and molecular changes in the healthy rodent brain. Sprague-Dawley rats (150–200 g) were intranasally administered buprenorphine (0.3 mg/mL) and sacrificed at different time points: 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h post drug administration. LC-MS was used to quantify BUP and neurotransmitters (GABA, GLUT, DA, NE and 5-HT) in the brain, while CREB and BDNF gene expression was determined using qPCR. Results showed that BUP reached a Cmax of 1.21 ± 0.0523 ng/mL after 2 h, with all neurotransmitters showing an increase in their concentration over time, with GABA, GLUT and NE reaching their maximum concentration after 8 h. DA and 5-HT reached their maximum concentrations at 1 h and 24 h, respectively post drug administration. Treatment with BUP resulted in significant upregulation in BDNF expression throughout the treatment period while CREB showed patterns of significant upregulation at 2 and 8 h, and downregulation at 1 and 6 h. This study contributes to the understanding of the pharmacodynamic effects of BUP in opioid addiction by proving that the drug significantly influences NT pathways that are implicated in opioid addiction.http://www.sciencedirect.com/science/article/pii/S0753332221003000BuprenorphineOpioid addictionBrain-derived neurotrophic factor (BDNF)Cyclic AMP response element-binding protein (CREB)Neurotransmitters